Accelerate discovery through
one of the world’s largest genetic
and phenotypic research platforms.

Explore consented data, build on published findings and collaborate with 23andMe on rigorous, large-scale studies of human health and disease.

  • Scale

    More than 11 million consented, genotyped participants.

  • Depth

    More than 4 billion phenotypic data points across health, traits and behaviors.

  • Recontactability

    Opportunities to engage eligible participants for follow-up studies.

  • Trust and rigor

    Research grounded in consent, privacy and independent ethics review.

Request a partnership discussion

More than80%Consent to research

Power your research
with an engaged, diverse, recontactable cohort.

Participation is online and IRB-approved, with participants free to opt in or out at any time — a model that sustains one of the most engaged cohorts in research.

How it works

  • Genetic Data

    • >500k variants genotyped, >150M variants imputed for ~8M individuals
    • Whole genome & whole exome sequence data for select cohorts

  • Survey Questions

    • Family history of disease
    • Diagnoses
    • Medication usage and response
    • Lifestyle / risk factors
    • Ancestry
    • On average: ~310 data points per customer

  • Real-World Data

    • Apple HealthKit
    • Google Fit
    • Electronic Health Records
    • Wearables
    • Clinical assessments (e.g., hearing and cognitive tests)

“Our new partnership with 23andMe supercharges the Mirador mission to rapidly advance transformational precision therapies for patients living with chronic immune-mediated inflammatory and fibrotic diseases.

Combining Mirador360’s cutting-edge biology, multi-modal data and AI capabilities with the unparalleled genetic and phenotypic insights from the 23andMe database will enable us to accelerate our progress toward solving major unmet needs in I&I.”

— Mark C. McKennaChairman and CEO of Mirador

6 ways to access 23andMe research data.

  • DISCOVER23

    GWAS access

    Explore pre-generated GWAS across 1,000+ disease cohorts and multiple ancestral populations, or request custom analyses through secure research access models.

  • INSIGHTS23

    Collaborative research

    Work with 23andMe scientists to support target validation, safety signal assessment, portfolio optimization and phenome-wide association research.

  • RECRUIT23

    Clinical trial recruitment

    Identify and engage eligible participants for clinical studies based on genetic, phenotypic or health-related criteria.

  • COHORT ACCESS

    Individual-level data

    Secure research environment access to individual-level genetic and phenotypic data. Biobank access also available.

  • COHORT DEEP DIVE

    Custom cohort design

    Deep exploration of a specific cohort, looking at disease, ancestry, wearables, health records and surveys. Includes recontactability for biomarker collection.

  • ENGAGE23

    Targeted survey design

    Engage the 23andMe research cohort to gather honest participant context on your research.

Request a partnership discussion

Explore the data.

Explore23 gives researchers a way to explore selected aggregate data and sample reports from 23andMe’s large-scale genetic and phenotypic research dataset.

Browse available cohort statistics, study summaries, survey completions, allele frequencies and example reports, including GWAS and burden tests.

Explore now

Work with our
team of experts.

  • Target validation based on human genetic evidence

    Drugs with human genetic evidence are 2x-3x more likely to succeed.

    Nelson et al., 2015 (Nature Genetics);
    King et al., 2019 (PLOS Genetics).

  • Uncover
    safety signals

    Genetic evidence is 2x more likely to predict side effects.

    Applicable from discovery stage
    through commercialization.

  • Optimize
    research programs

    Identify new indications or opportunities to out-license.

Learn more

We publish what we learn. 300+ peer-reviewed papers and counting.

An illustration of a human brain rendered in light, with bright points scattered through it.
Publication

Genetic analysis and natural history of Parkinson’s disease due to the LRRK2 G2019S variant

Brain · 2024Read paper
A close crop of a woman holding a slice of orange to her nose and mouth.
Publication

The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste

Nature Genetics · 2022Read paper
View all publications

Research Integrity & Governance

  • IRB oversight

    23andMe Research Institute works with an independent, nonprofit, AAHRPP-accredited Institutional Review Board for oversight of all research studies. Every research protocol and consent process undergoes mandatory IRB review before we begin.

  • Common Rule compliance

    Our processes meet or exceed federal research standards. Every study is ethically sound before a single data point is collected.

  • Informed, opted-in cohorts

    Participants explicitly opt in. Automated real-time withdrawal processing maintains a clean, compliant dataset for partners.

See more details

Analyze data securely within 23andMe’s controlled research environment.

No data leaves the secure environment unless explicitly approved through export review.

Integration with your organization's SSO. 23andMe enforces additional 2FA, membership controls and access policies.

Every partner operates in their own isolated account. Only select team members can access partner workspaces.

Ready to advance
your research and collaborate?

Talk to our partnerships team about which access model fits your research program.

Request a partnership discussion.

Request a partnership discussionBrowse Explore23View Publications